Citadel Advisors
GSK icon

Citadel Advisors’s GSK GSK Stock Holding History

Citadel Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.2M Buy
582,900
+97,900
+20% +$5.31M 0.01% 1786
2025
Q4 		$23.8M Buy
485,000
+59,200
+14% +$2.76M ﹤0.01% 2159
2025
Q3 		$18.4M Buy
425,800
+12,800
+3% +$500K ﹤0.01% 2447
2025
Q2 		$15.9M Sell
413,000
-48,200
-10% -$1.84M ﹤0.01% 2429
2025
Q1 		$17.9M Sell
461,200
-338,100
-42% -$12.4M ﹤0.01% 2174
2024
Q4 		$27M Buy
799,300
+579,800
+264% +$20.9M ﹤0.01% 1849
2024
Q3 		$8.97M Buy
219,500
+13,000
+6% +$532K ﹤0.01% 3086
2024
Q2 		$7.95M Buy
206,500
+16,100
+8% +$677K ﹤0.01% 3074
2024
Q1 		$8.16M Sell
190,400
-100,940
-35% -$4.16M ﹤0.01% 3203
2023
Q4 		$10.8M Sell
291,340
-185,320
-39% -$6.65M ﹤0.01% 2736
2023
Q3 		$17.3M Buy
476,660
+39,260
+9% +$1.39M ﹤0.01% 2017
2023
Q2 		$15.6M Sell
437,400
-73,040
-14% -$2.62M ﹤0.01% 2138
2023
Q1 		$18.2M Sell
510,440
-389,280
-43% -$13.6M ﹤0.01% 2022
2022
Q4 		$31.6M Sell
899,720
-1,577,500
-64% -$52.5M 0.01% 1508
2022
Q3 		$72.9M Buy
2,477,220
+1,598,980
+182% +$60.6M 0.02% 792
2022
Q2 		$47.8M Buy
878,240
+194,320
+28% +$10.7M 0.01% 1050
2022
Q1 		$37.2M Buy
683,920
+58,560
+9% +$3.18M 0.01% 1347
2021
Q4 		$34.5M Sell
625,360
-141,120
-18% -$7.34M 0.01% 1486
2021
Q3 		$36.6M Buy
766,480
+143,600
+23% +$7.21M 0.01% 1369
2021
Q2 		$31M Buy
622,880
+304,720
+96% +$14.6M 0.01% 1576
2021
Q1 		$14.2M Buy
318,160
+203,440
+177% +$9.23M ﹤0.01% 2456
2020
Q4 		$5.28M Sell
114,720
-8,640
-7% -$397K ﹤0.01% 3587
2020
Q3 		$5.8M Buy
123,360
+720
+0.6% +$36.1K ﹤0.01% 2939
2020
Q2 		$6.25M Sell
122,640
-63,680
-34% -$3.27M ﹤0.01% 2771
2020
Q1 		$8.82M Buy
186,320
+76,080
+69% +$4.06M ﹤0.01% 2005
2019
Q4 		$6.47M Sell
110,240
-86,720
-44% -$4.82M ﹤0.01% 2753
2019
Q3 		$10.5M Buy
196,960
+64,640
+49% +$3.33M 0.01% 2159
2019
Q2 		$6.62M Sell
132,320
-22,720
-15% -$1.14M ﹤0.01% 2703
2019
Q1 		$8.1M Sell
155,040
-148,000
-49% -$7.4M ﹤0.01% 2326
2018
Q4 		$14.5M Sell
303,040
-115,840
-28% -$5.7M 0.01% 1505
2018
Q3 		$21M Buy
418,880
+234,960
+128% +$11.9M 0.01% 1350
2018
Q2 		$9.27M Sell
183,920
-14,400
-7% -$725K ﹤0.01% 2024
2018
Q1 		$9.69M Sell
198,320
-73,680
-27% -$3.43M 0.01% 1773
2017
Q4 		$12.1M Buy
272,000
+77,040
+40% +$3.56M 0.01% 1556
2017
Q3 		$9.89M Buy
194,960
+55,280
+40% +$2.8M 0.01% 1616
2017
Q2 		$7.53M Buy
139,680
+86,720
+164% +$4.62M 0.01% 1711
2017
Q1 		$2.79M Sell
52,960
-142,160
-73% -$7.21M ﹤0.01% 2673
2016
Q4 		$9.39M Buy
195,120
+155,760
+396% +$7.69M 0.01% 1413
2016
Q3 		$2.12M Sell
39,360
-33,280
-46% -$1.82M ﹤0.01% 2906
2016
Q2 		$3.94M Buy
+72,640
New +$3.83M ﹤0.01% 2036

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors's GSK Position: Q1 2026 in Review

Citadel Advisors sold out of GSK (GSK) in Q1 2026, closing a stake of 214,099 shares — an estimated $11.6M sold.

Citadel Advisors first reported a position in GSK in Q2 2013 and held it in 47 quarters. The position peaked at $109M in Q3 2022. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Citadel Advisors reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 214,099 GSK shares in Q1 2026, an estimated $11.6M.
  • Citadel Advisors first reported a position in GSK in Q2 2013 and held it in 47 quarters.
  • Citadel Advisors's GSK position peaked at $109M in Q3 2022.
  • 1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.